KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Intangibles (2016 - 2022)

Ionis Pharmaceuticals has reported Intangibles over the past 14 years, most recently at $29.6 million for Q3 2022.

  • Quarterly results put Intangibles at $29.6 million for Q3 2022, down 1.44% from a year ago — trailing twelve months through Sep 2022 was $29.6 million (down 1.44% YoY), and the annual figure for FY2021 was $29.0 million, up 3.82%.
  • Intangibles for Q3 2022 was $29.6 million at Ionis Pharmaceuticals, up from $29.1 million in the prior quarter.
  • Over the last five years, Intangibles for IONS hit a ceiling of $30.0 million in Q3 2021 and a floor of $22.9 million in Q1 2018.
  • Median Intangibles over the past 5 years was $27.7 million (2020), compared with a mean of $27.1 million.
  • Biggest five-year swings in Intangibles: increased 12.31% in 2019 and later dropped 1.44% in 2022.
  • Ionis Pharmaceuticals' Intangibles stood at $24.0 million in 2018, then grew by 6.83% to $25.7 million in 2019, then increased by 8.81% to $27.9 million in 2020, then grew by 3.82% to $29.0 million in 2021, then rose by 2.07% to $29.6 million in 2022.
  • The last three reported values for Intangibles were $29.6 million (Q3 2022), $29.1 million (Q2 2022), and $29.3 million (Q1 2022) per Business Quant data.